

6 January 2025

**ASX Market Announcements** ASX Limited Level 4 Stock Exchange Centre 20 Bridge Street SYDNEY NSW 2000

## **RESULTS OF GENERAL MEETING**

Respiri Limited (ASX:RSH; OTCQB:RSHUF)("Respiri" or the "Company"), ) hereby provides the results of its general meeting of shareholders held on 6 January 2025.

Information required to be disclosed by the Company in accordance with Listing Rule 3.13.2 and Section 251AA(2) of - the Corporations Act is attached.

All resolutions were passed on a poll. Details of resolutions, the proxies received, and the votes cast on the poll in Urespect of each resolution are set out in the attached results summary.

For and on behalf of the Board:

OFor further information, investors and media please contact:

Mr Marjan Mikel **CEO & Managing Director** Respiri Limited P: +61 408 462 873 E: marjan@respiri.co

Mr Nicholas Smedley **Executive Chairman Respiri Limited** P: +61 447 074 160 E: nicholas@respiri.co

This ASX announcement has been authorised for release by the Board of Directors of Respiri Limited.

## About Respiri Limited

Respiri is an e-Health SaaS company supporting respiratory health management and Remote Patient Monitoring services. Its world-first technology detects wheeze, a typical symptom of asthma, COPD and respiratory disease to provide an objective measure of airway limitation. wheezo®, Respiri's innovative technology, comprises an eHealth app combined with a simple, easy to use, handheld device. wheezo® is the first smart device to help improve asthma management by monitoring wheeze and documenting symptoms, signs, triggers, weather conditions and medication use. The asthma management platform also facilitates the sharing of data with caregivers, physicians and other health care professionals.

Respiri's mission is to help improve quality of life for hundreds of millions of children and adults around the world and dramatically reduce hospital admissions and the economic burden of asthma. Respiri Limited's operations are based in Melbourne, Australia and in New York, USA.

For additional information about Respiri and its products, please visit www.respiri.co



## About wheezo®

Developed in Australia, with the support of respiratory specialists and other healthcare professionals, the innovative wheezo® device analyses breath sounds for wheeze, and the eHealth App assists patients with managing their asthma by tracking symptoms, triggers, medication use and geo-specific weather conditions. The platform has been designed to extend asthma management beyond the clinic and make it easy to share information with doctors and make appropriate adjustments to asthma action plans. Better active management may lead to better outcomes and improved quality of life for the asthma patient.

For further information about wheezo®, follow the online link https://wheezo.com

wheezo® is a registered trademark of Respiri Limited.

LĹ



## Respiri Limited 2025 General Meeting Monday, 6 January 2025 - Voting Results

The following information is provided in accordance with section 251AA(2) of Corporations Act 2001 (Cth)

UO C	Resolution Details (S) Poll			Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Res. Results
nse	Resolution	Resolution Type	S or P	For	Against	Proxy's Discretion	Abstain/ Excluded	For	Against	Abstain	Carried/ Not Carried
	Approval to issue Initial Consideration Shares to Orb Health, Inc.	Ordinary	Ρ	376,031,280 99.17%	1,799,753 0.47%	1,383,680 0.36%	38,500	378,059,278 99.53%	1,799,753 0.47%	38,500	Carried
S D 2.	Approval to issue Additional Shares to Orb Health, Inc.	Ordinary	Р	376,018,561 99.16%	1,812,472 0.48%	1,383,680 0.36%	38,500	377,402,241 99.52%	1,812,472 0.48%	682,818	Carried
d. Jo	Ratification and approval of prior issue of Shares	Ordinary	Р	375,179,535 98.94%	2,651,498 0.70%	1,383,680 0.36%	38,500	376,563,215 99.30%	2,651,498 0.70%	682,818	Carried

\*Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.